This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA experts were retained by counsel for the plaintiff in connection with an application for a preliminary injunction involving the manufacturing of a biologic product in Denmark.
Dr. Andrew Tepperman submitted a declaration and testified in court, addressing the economic and commercial factors that would influence the magnitude of a potential loss if a preliminary injunction were granted and later found to be unjustified.
Several pivotal topics emerged, establishing predominant themes throughout the conference. Although efficacy continues to be the fundamental basis of oncology...
The relationship between ASP dynamics and changes to WAC, both publicly available, offers insight into the apparent level of price concessions for a product....
Is Going to a Private-Equity Owned Hospital Bad for Your Health? Private equity investment in health care has increased more than 20-fold—from $5 billion in...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
